PathWhiz

PathWhiz ID	Pathway	Meta Data
PW145287 View Pathway	drug action Bromocriptine Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:28 Last Updated: October 07, 2023 at 15:28
PW176520 View Pathway	metabolic Bromhexine Predicted Metabolism Pathway Homo sapiens Metabolites of Bromhexine are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 13, 2023 at 13:53 Last Updated: December 13, 2023 at 13:53
PW145923 View Pathway	drug action Bromhexine Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:58 Last Updated: October 07, 2023 at 16:58
PW127971 View Pathway	drug action Bromfenac NSAID Action Pathway Homo sapiens Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity. The mechanism of its action is due to the ability of bromfenac to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2 with selectivity for COX-2 over COX-1. Prostaglandins are mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Daphnee Created On: June 26, 2023 at 10:20 Last Updated: June 26, 2023 at 10:20
PW145061 View Pathway	drug action Bromfenac Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:00 Last Updated: October 07, 2023 at 15:00
PW000259 View Pathway	drug action Bromfenac Action Pathway Homo sapiens Bromfenac (also named Prolensa, Bromday or Xibrom) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to reduce ocular inflammation and pain after cataract surgery. Bromfenac is also a type of ophthalmic anti-inflammatory medicines. Bromfenac can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis in many animal model's cell is caused by presence of bromfenac. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 22, 2013 at 10:45 Last Updated: August 22, 2013 at 10:45
PW175983 View Pathway	metabolic Bromazepam Predicted Metabolism Pathway new Homo sapiens Metabolites of Bromazepam are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: November 29, 2023 at 13:00 Last Updated: November 29, 2023 at 13:00
PW145443 View Pathway	drug action Bromazepam Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:50 Last Updated: October 07, 2023 at 15:50
PW126603 View Pathway	drug action Bromazepam Action Pathway Homo sapiens Bromazepam is a short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety. Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action. Bromazepam allosterically binds on the benzodiazepine receptors in the post-synaptic GABA-A ligand-gated chloride channel in different sites of the central nervous system (CNS). This binding will result in an increase on the GABA inhibitory effects which is translated as an increase in the flow of chloride ions into the cell causing hyperpolarization and stabilization of the cellular plasma membrane, ultimately leading to a sedative-like effect. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Karxena Harford Created On: January 25, 2022 at 21:59 Last Updated: January 25, 2022 at 21:59
PW128528 View Pathway	drug action Brolucizumab Action Pathway Homo sapiens Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration. It functions as a vascular endothelial growth factor (VEGF) inhibitor, specifically targeting major VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). By inhibiting these isoforms, brolucizumab reduces the proliferation of endothelial cells, vascularization of tissue, and permeability of blood vessels, which are processes associated with neovascular AMD. It has a relatively long duration of action, typically administered on a monthly basis. Patients should be informed about potential risks, including endophthalmitis, retinal detachment, and arterial thromboembolic events, associated with this medication. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 13:30 Last Updated: September 01, 2023 at 13:30